UK National Screening Committee Report Singles Out Eyenuk’s EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health Service

UK National Screening Committee Report Singles Out Eyenuk’s EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health ServiceGlobeNewswireJune 01, 2022

LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announced today that its EyeArt® system has been confirmed to have “sufficient high quality evidence” as “safe and cost-effective,” and is the only diabetic eye screening AI technology ready for live clinical implementation in the United Kingdom, according to the report, Automated grading in the Diabetic Eye Screening Programme- External review against programme appraisal criteria for the UK National Screening Committee.”

The comprehensive review of 10 AI algorithms’ performance, reported in peer-reviewed publications, was conducted for the UK National Screening Committee (NSC), which provides advice about all aspects of population screening to the National Health Service (NHS) and the ministers of the four UK countries (England, Scotland, Wales, and Northern Ireland).

The 169-page NSC report identified the EyeArt v2.1 algorithm for autonomous diabetic retinopathy screening as the only AI technology ready for live clinical implementation in the UK. Study authors concluded that “there is sufficient high-quality evidence from the EDESP (English Diabetic Eye Screening Program) that EyeArt v2.1 may be safe and cost-effective either using it for level 1 grading or as a filter prior to manual grading.”

The EyeArt system is now being planned for live clinical use within the North East London NHS Diabetes Eye Screening Programme as part of a project led by the Moorfields Eye Hospital NHS Foundation Trust and supported jointly by the NHSX AI Lab and the UK Health Foundation. The funded program will implement the live clinical use of artificial intelligence and assess its effectiveness in addressing racial and ethical health inequalities, and its acceptability by healthcare providers and people with diabetes.

“We are gratified by the NSC’s confirmation that the EyeArt system stands out from other solutions for its safety and cost-effectiveness and would like to thank our clinical collaborators within various diabetes eye screening programs (DESP) throughout the National Health Service,” said Kaushal Solanki, PhD, founder and CEO of Eyenuk. “We look forward to working with the Moorfields Eye Hospital and the North East London NHS DESP to deploy the EyeArt system for live clinical use.”

The UK has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually). In most countries, fewer than half of diabetes patients receive annual eye screening. Thanks to the UK’s comprehensive screening program, it is the only country where diabetic retinopathy is no longer the leading cause of blindness in the working-age adults.

Eyenuk will showcase the EyeArt AI System during the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7. Attendees can visit booth #1709 to learn how the EyeArt system can help their organizations improve diabetes management and population health.

About Eyenuk, Inc.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease. Find Eyenuk online on its website, Twitter, Facebook, and LinkedIn.

About the EyeArt AI System
The EyeArt AI System provides fully autonomous diabetic retinopathy (DR) screening, including retinal imaging, DR detection based on international clinical standards and immediate reporting, in a single office visit during a diabetic patient’s regular exam. Once the patient’s fundus images have been captured and submitted to the EyeArt AI System, the DR detection results are available in a PDF report in less than 30 seconds.

The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). In addition to U.S. Food and Drug Administration (FDA) 510(k) clearance, the EyeArt AI System has CE marking as a class 2a medical device in the European Union and a Health Canada license. It is the most extensively validated AI technology for autonomous DR detection, tested on over 500,000 patients globally with 2 million images collected in clinical environments. It is designed to be General Data Protection Regulation (GDPR) and Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. The EyeArt AI System is reimbursable by government and private payors in the U.S. under the newly created Category 1 Current Procedural Terminology (CPT) code 92229.

VIDEO: Learn more about the EyeArt AI System for Autonomous Detection of Diabetic Retinopathy

Media Contact
Todd Stein
+1 510 417 0612
todd@toddsteincommunications.com

Eyenuk, Inc. Contact
Frank Cheng, President & CCO
+1 818 835 3585
frank.cheng@eyenuk.com


Primary Logo